High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder

Journal of Neuro-Oncology

Volumn 103, Issue 3, 2011, Pages 739-743

  Patrick, A ^a   Wee, A ^a   Hedderman, A ^a   Wilson, D ^a   Weiss, J ^a   Govani, M ^a  

^a ST VINCENT HOSPITAL   (United States)

Author keywords

Kidney transplantation; Posttransplant lymphoproliferative disorder; Primary CNS PTLD; Rituximab

Indexed keywords

GADOLINIUM; RITUXIMAB;

ABNORMAL RESPIRATORY SOUND; ADULT; ARTICLE; BRAIN BIOPSY; CASE REPORT; CAUDATE NUCLEUS; COMPUTER ASSISTED TOMOGRAPHY; CRACKLES; DRUG DOSE ESCALATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY CENTRAL NERVOUS SYSTEM POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; THALAMUS; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; CENTRAL NERVOUS SYSTEM DISEASES; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79959791883     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0425-0     Document Type: Article

References (22)

1. Schneck SA, Penn I (1970) Cerebral neoplasms associated with renal transplantation. Arch Neurol 22:226-233
2. Phan TG, O'Neill BP, Kurtin PJ (2000) Posttransplant primary CNS lymphoma. Neurooncology 2:229-238
3. Snanoudj R, Durrbach A, Leblond V et al (2003) Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation 76:930-937 (Pubitemid 37186022)
4. Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ (2004) Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 121:246-253 (Pubitemid 38140130)
5. Cavaliere R, Petroni G, Lopes M, Schiff D, The International Primary Central Nervous System Lymphoma Collaborative Group (2010) Primary central nervous system post-transplantation lymphoproliferative disorder. Cancer 116:863-870
6. Penn I, Porat G (1995) Central nervous system lymphomas in organ allograft recipients. Transplantation 59:240-244
7. Buell JF, Gross TG, Hanaway MJ et al (2005) Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc 37:954-955 (Pubitemid 40590756)
8. Caillard S, Dharnidharka, Agodoa L, Bohen E, Abbott K (2005) Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80:1233-1243 (Pubitemid 41746802)
9. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW (2009) Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplant center. J Clin Oncol 27:3354-3362
10. Blaes AH, Peterson BA, Bartlett N et al (2005) Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation. Cancer 104:1661-1667 (Pubitemid 41437429)
11. Choquet S, Leblond V, Herbrecht R et al (2006) Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of prospective multicenter phase 2 study. Blood 107:3053-3057
12. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ et al (2007) Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 92:1489-1494 (Pubitemid 350144124)
13. Ruhstaller TW, Amsler U, Cerny T (2000) Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma. Ann Oncol 11:374-375 (Pubitemid 30214681)
14. Harjunpaa A, Wiklund T, Collan J et al (2001) Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 42:731-738 (Pubitemid 32782781)
15. Rubenstein JL, Combs D, Rosenberg J et al (2003) Rituximab therapy for CNS lymphoma: targeting the leptomeningeal compartment. Blood 101:466-468 (Pubitemid 36077565)
16. Traum AZ, Rodig NM, Pilichowska ME, Somers MJG (2006) Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients. Pediatr Transplant 10:505-512 (Pubitemid 43780687)
17. O'Brien SM, Kantarjian H, Thomas DA et al (2001) Rituximab dose escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170 (Pubitemid 32366970)
18. Kordelas L, Trenschel R, Koldehoff M, Elmaagacli A, Beelen DW (2008) Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Onkologie 31:691-693
19. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U (2004) Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89:753-754 (Pubitemid 38828486)
20. Rubenstein JL, Fridlyand J, Abrey L et al (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25:1350-1356 (Pubitemid 46706881)
21. Wong ET, Tishler R, Barron L, Wu JK (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101:139-145 (Pubitemid 38812433)
22. Angelov L, Doolittle ND, Kraemer DF et al (2009) Blood brain barrier disruption and methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-iinstitutional experience. J Clin Oncol 27:3503-3509